These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 35894071

  • 1. Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort.
    Guellec D, Carvajal-Alegria G, Daïen C, Gossec L, Guillemin F, Berenbaum F, Constantin A, Dieude P, Dougados M, Flipo RM, Goupille P, Mariette X, Richez C, Vittecoq O, Combe B, Saraux A.
    Clin Exp Rheumatol; 2023 Mar; 41(3):649-655. PubMed ID: 35894071
    [Abstract] [Full Text] [Related]

  • 2. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [Abstract] [Full Text] [Related]

  • 3. Databases of patients with early rheumatoid arthritis in the USA.
    Sokka T, Willoughby J, Yazici Y, Pincus T.
    Clin Exp Rheumatol; 2003 May; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
    [Abstract] [Full Text] [Related]

  • 4. Prevalence and clinical significance of extra-articular manifestations at diagnosis in the ESPOIR cohort with recent-onset arthritis.
    Guellec D, Cozien S, Ruyssen-Witrand A, Dieudé P, Saraux A.
    Semin Arthritis Rheum; 2020 Jun; 50(3):409-413. PubMed ID: 32067722
    [Abstract] [Full Text] [Related]

  • 5. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
    van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH.
    Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
    [Abstract] [Full Text] [Related]

  • 6. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B.
    Arthritis Res Ther; 2019 Nov 15; 21(1):243. PubMed ID: 31730497
    [Abstract] [Full Text] [Related]

  • 7. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.
    J Rheumatol; 2013 Oct 15; 40(10):1650-7. PubMed ID: 23950185
    [Abstract] [Full Text] [Related]

  • 8. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y, Desai RJ, Liu J, Choi NK, Kim SC.
    Arthritis Res Ther; 2017 Jul 05; 19(1):159. PubMed ID: 28679392
    [Abstract] [Full Text] [Related]

  • 9. Impact of multimorbidity on disease modifying antirheumatic drug therapy in early rheumatoid arthritis: Data from the ESPOIR cohort.
    Beltai A, Combe B, Coffy A, Gaujoux-Viala C, Lukas C, Saraux A, Dougados M, Daurès JP, Hua C.
    Joint Bone Spine; 2022 May 05; 89(3):105326. PubMed ID: 34906696
    [Abstract] [Full Text] [Related]

  • 10. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S.
    Am J Med; 2015 May 05; 128(5):539.e7-17. PubMed ID: 25534420
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
    Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T, QUEST-RA Group.
    Arthritis Res Ther; 2008 May 05; 10(2):R30. PubMed ID: 18325087
    [Abstract] [Full Text] [Related]

  • 13. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.
    Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM.
    PLoS Med; 2020 Sep 05; 17(9):e1003296. PubMed ID: 32960885
    [Abstract] [Full Text] [Related]

  • 14. Disease Characteristics and Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-year Followup Study.
    Brinkmann GH, Norli ES, Kvien TK, Haugen AJ, Grøvle L, Nygaard H, Bjørneboe O, Thunem C, Mjaavatten MD, Lie E.
    J Rheumatol; 2017 Feb 05; 44(2):154-161. PubMed ID: 28089976
    [Abstract] [Full Text] [Related]

  • 15. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
    Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X.
    Arthritis Res Ther; 2012 Nov 19; 14(6):R249. PubMed ID: 23164197
    [Abstract] [Full Text] [Related]

  • 16. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.
    Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, Dougados M, Fautrel B, Flipo RM, Goupille P, Mariette X, Saraux A, Schaeverbeke T, Sibilia J, Vittecoq O, Daurès JP.
    Rheumatology (Oxford); 2021 Nov 03; 60(11):5073-5079. PubMed ID: 33961011
    [Abstract] [Full Text] [Related]

  • 17. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Nov 03; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 18. Long-term impact of delay in assessment of patients with early arthritis.
    van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga TW, van der Helm-van Mil AH.
    Arthritis Rheum; 2010 Dec 03; 62(12):3537-46. PubMed ID: 20722031
    [Abstract] [Full Text] [Related]

  • 19. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009.
    Kim SC, Yelin E, Tonner C, Solomon DH.
    Arthritis Care Res (Hoboken); 2013 Sep 03; 65(9):1529-33. PubMed ID: 23463543
    [Abstract] [Full Text] [Related]

  • 20. The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.
    Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J, Schaeverbeke T, Bourgeois P, Ravaud P, Fautrel B.
    J Rheumatol; 2009 May 03; 36(5):934-42. PubMed ID: 19286850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.